期刊文章部分封锁前后法国COVID-19传播源的自我评估分析:卡塔尔世界杯8强波胆分析观察研究%A Denis,Fabrice %A Septans,Anne-Lise %A Le Goff,Florian %A Jeanneau,Stephan %A Lescure,François-Xavier %+地区间癌症研究所Jean Bernard - ELSAN，勒芒，Rue Beauverger，法国，33 0684190480，fabrice.denis.home@gmail.com %K COVID-19 %K web应用%K数字健康%K分析%K传播%K法国%K自我评估%K封锁%K观察%K调查%K影响%K公共卫生%D 2021 %7 4.5.2021 %9原创论文%J J医学互联网Res %G英语%X背景:我们针对一个web应用开发了一份问卷，用于分析第二波大流行期间法国的COVID-19污染情况。目的:本研究旨在分析法国第二次部分封城前后对污染特征的影响，以调整公共卫生限制措施，进一步防止大流行疫情激增。方法:在2020年12月15日至24日期间，在一场全国媒体宣传活动之后，对sourcecovid.fr web应用程序的用户提出了关于他们自己或近亲属在2020年8月15日之后在法国感染COVID-19的问题。对污染情况的数据进行了评估和比较，第二次部分封锁发生在第二波大流行期间的2020年10月25日，并于2020年12月24日持续进行。结果:截至2020年12月24日，该web应用程序上观察到44.1万个连接。共有2218份问卷可供评估分析。约61.8% (n=1309)的参与者确定其污染来源，38.2% (n=809)的参与者认为他们知道污染来源。用户的中位年龄为43.0岁(IQR 32-56)，其中50.7% (n=1073)为男性。 The median incubation time of the assessed cohort was 4.0 (IQR 3-5) days. Private areas (family’s or friend’s house) were the main source of contamination (1048/2090, 50.2%), followed by work colleagues (579/2090, 27.7%). The main time of day for the contamination was the evening (339/961, 35.3%) before the lockdown and was reduced to 18.2% (86/473) after the lockdown (P<.001). The person who transmitted the virus to the user before and after the lockdown was significantly different (P<.001): a friend (382/1317, 29% vs 109/773, 14.1%), a close relative (304/1317, 23.1% vs 253/773, 32.7%), or a work colleague (315/1317, 23.9% vs 264/773, 34.2%). The main location where the virus was transmitted to the users before and after the lockdown was significantly different too (P<.001): home (278/1305, 21.3% vs 194/760, 25.5%), work (293/1305, 22.5% vs 225/760, 29.6%), collective places (430/1305, 33% vs 114/760, 15%), and care centers (58/1305, 4.4% vs 74/760, 9.7%). Conclusions: Modalities of transmissions significantly changed before and after the second lockdown in France. The main sources of contamination remained the private areas and with work colleagues. Work became the main location of contamination after the lockdown, whereas contaminations in collective places were strongly reduced. Trial Registration: ClinicalTrials.gov NCT04670003; https://clinicaltrials.gov/ct2/show/NCT04670003 %M 33878018 %R 10.2196/26932 %U //www.mybigtv.com/2021/5/e26932 %U https://doi.org/10.2196/26932 %U http://www.ncbi.nlm.nih.gov/pubmed/33878018